Abstract: Diabetic macular edema (DME) is the main cause of visual impairment in diabetic retinopathy (DR). At present, anti-vascular endothelial growth factor (anti-VEGF) drugs, especially aflibercept, have been widely used in clinical practice as the first-line treatment for DME, and have achieved good results. The advantages of arbocept are strong affinity, multiple targets and long half-life, etc. Current studies have shown that arbocept is more suitable for DME patients with baseline visual acuity of 20/50 or worse, and a more optimized delivery mode is still under further exploration. (Int Rev Ophthalmol, 2022, 46: 74-78)

Key words: diabetic retinopathy, diabetic macular edema, anti-VEGF, aflibercept